



Praxis Precision Medicines to Participate in Upcoming Investor Conferences

May 17, 2024 at 8:00 AM EDT

BOSTON, May 17, 2024 (GLOBE NEWSWIRE) -- [Praxis Precision Medicines](#), Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will be participating in three upcoming conferences.

- Praxis management will participate in a fireside chat at the **H.C. Wainwright 2nd Annual BioConnect Investor Conference**, taking place in New York, NY at the NASDAQ Stock Exchange on May 20, 2024 at 10:00am EDT. A live webcast of the fireside chat will be available through this [link](#) and will also be available through the "Upcoming & Recent Events" page of the Investors + Media section of the company's website www.praxismedicines.com. A replay of the webcast will be available on Praxis' website for 90 days following the event.
- Praxis management will also participate in the **Mizuho Securities USA Neuroscience Summit**, taking place in Boston, MA on May 21, 2024.
- Praxis management will also be participating in a fireside chat at the **Jefferies Global Healthcare Conference**, taking place in New York, NY on June 6, 2024 at 11:30am EDT. A live webcast of the fireside chat will be available through this [link](#) and will also be available through the "Upcoming & Recent Events" page of the Investors + Media section of the company's website www.praxismedicines.com. A replay of the webcast will be available on Praxis' website for 90 days following the event.

About Praxis

Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across movement disorders and epilepsy, with four clinical-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on [Facebook](#), [LinkedIn](#) and [Twitter/X](#).

Investor Contact: Praxis Precision Medicines investors@praxismedicines.com 857-702-9452 Media Contact: Dan Ferry Life Science Advisors Daniel@lifesciadvisors.com 617-430-7576